Taysha Gene Therapies (TSHA) Change in Cash (2020 - 2026)

Taysha Gene Therapies (TSHA) has 7 years of Change in Cash data on file, last reported at -$43.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash fell 92.45% year-over-year to -$43.2 million; the trailing twelve-month figure through Mar 2026 stood at $160.1 million (up 2267.96% YoY), and the FY2025 full-year result was $180.9 million, up 3788.72% from the prior year.
• Change in Cash fell to -$43.2 million in Q1 2026, from $22.6 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $196.2 million in Q2 2025 to a low of -$52.5 million in Q1 2022.
• A 5-year average of $7.5 million and a median of -$18.7 million in 2024 frame the typical range for Change in Cash.
• Across the five-year window, Change in Cash plunged 436.06% in 2022 and soared 473.27% in 2023, its largest moves.
• Tracing TSHA's Change in Cash over 5 years: stood at $53.6 million in 2022, then tumbled by 138.03% to -$20.4 million in 2023, then rose by 8.46% to -$18.7 million in 2024, then jumped by 221.1% to $22.6 million in 2025, then slumped by 291.22% to -$43.2 million in 2026.
• Business Quant data shows TSHA's Change in Cash at -$43.2 million in Q1 2026, $22.6 million in Q4 2025, and -$15.4 million in Q3 2025.